Introduction
Average life expectancy has increased by 10 years in the last 30 years with improvements in the field of cardiology contributing for at least 7 years [1] . Despite such success, coronary artery disease (CAD) remains the leading cause of mortality and morbidity in the world [24] . It follows that the cardiovascular community has not solved the problem, but has delayed the occurrence of CAD-related mortality and changed the demographics of patients with CAD, with a shift of disease burden toward older patients, in both men and women [5, 6] .
Aging has been associated with a reduced likelihood of receiving effective cardiac therapies [710] . Furthermore, the prevention and treatment of CAD may not be as effective in women as in men [1118] , suggesting that for optimal treatment of CAD it is necessary to recognize the impact of age and gender differences on the outcomes of care.
Surprisingly, there is a paucity of contemporary data regarding the clinical characteristics and management of outpatients with stable CAD. The majority of data are restricted to a particular manifestation of disease such as angina or acute coronary syndrome [6, 14, 1924] and are limited to a specific country or a geographic area. Furthermore, gender and age are usually analyzed separately [21, 22, 2426] . Our goal is to describe the gender-and age-based differences in baseline characteristics and management of outpatients with stable CAD using a large contemporary database from 45 countries.
Methods

Study design
CLARIFY is an ongoing international, prospective, observational, longitudinal cohort study in stable CAD outpatients with a 5-year follow-up [27] . Patients were enrolled in 45 countries in Africa, Asia, Australia, Europe, the Middle East, and North, Central and South America. They were treated according to usual clinical practice at each institution, with no specific tests or therapies defined in the study protocol. CLARIFY is registered in the ISRCTN registry of clinical trials with the number ISRCTN43070564 and approved 4 by local ethical committees. All subjects provided written informed consent in accordance with national and local guidelines.
Study population
Outpatients with stable CAD had to meet at least one of the following criteria to be eligible for enrollment [27] : documented myocardial infarction > 3 months previously; at least one angiographically proved >50% diameter coronary artery stenosis; chest pain with myocardial ischemia proven by stress echocardiography (ECG), or myocardial imaging; and history of coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) carried out > 3 months previously. Patients were not eligible if they had been hospitalized for cardiovascular disease (CVD) within the last 3 months 
Baseline data collection and data management
Data regarding patient demographics, medical history, risk factors, employment status, physical examination, heart rate (determined by both pulse palpation and 12-lead electrocardiography) using the most recent ECG within 6 months in clinically stable patients, laboratory values (if available), and current chronic medical treatments were collected by the participating physician using an electronic case report form and sent to the data management center. Here, data were checked for completeness and internal consistency. Data quality control was performed onsite in 5% of sites chosen at random 5 in each country. At each of these sites, 100% of case report forms for patients enrolled at that site were monitored for source documentation and accuracy.
Statistical analysis
Data were collected and analyzed by an independent statistics center, the Robertson Center for Biostatistics, University of Glasgow, UK. Continuous variables are presented as means and standard deviations (SDs) in case of normal distribution, or medians and interquartile ranges (IQRs) and ranges in case of non-normal distribution. Categorical data are presented as counts and percentages.
Results
The CLARIFY registry screened a total of 33 432 patients from 45 countries. Baseline data were available for 33 280; 47 patients did not meet the inclusion criteria and 105 did not provide consent.
The mean (SD) age of the population surveyed was 64 (10.5) years. Women represented 22.5% of the population overall and were slightly older than the men with a mean age of 66.6 (10.0) years compared with 63.4 (10.5) years in men. A total of 17 206 patients were <65 years old, 10 812 were aged 65-74 years, and 5196 were aged ≥75 years.
Gender differences in the presentation and clinical management of outpatients with CAD
The baseline data for men and women are presented in Tables 1 and 2 . A number of important differences in clinical characteristics and management were identified.
Compared with men, women were on average 3.1 years older and had higher resting heart rates (69.0 bpm versus 67.9 bpm, pulse palpation) and systolic blood pressure In terms of cardiovascular history, women had a shorter duration of CAD (4 years versus 5 years, P<0.0001) and were more frequently diagnosed with diabetes, hypertension, stroke, and transient ischemic attack. Smoking, a history of myocardial infarction, and peripheral arterial disease (PAD) were more common in men. Women presented with angina more often than men (28% versus 20%) and this was true for all angina classes defined by the Canadian Cardiovascular Society grading scale (Fig. 1) . In contrast, women were less likely to have undergone PCI (54.9% versus 59.8%) or CABG (17.8% versus 25.0%) (Fig. 2 ).
Women were less likely to have undergone cardiac investigations. Coronary angiography was performed in 79.9% of women versus 87.0% of men. Noninvasive tests for myocardial ischemia were done in 58.3% of women compared with 62.9% in men. In those patients with data from noninvasive testing, evidence for myocardial ischemia was observed more often in women than men (17.3% vs 15.9%).
Women were prescribed angiotensin-converting enzyme (ACE) inhibitors and lipidlowering drugs significantly less frequently than men, but received antianginal agents, antidiabetes drugs, non-steroidal anti-inflammatory, proton pump inhibitor, and thyroid hormone replacement more often than men (Fig. 2) . There was no significant difference in the use of beta-blockers between the sexes. Table 1 demonstrates that concomitant conditions were widely prevalent among the study population. The proportion of those with atrial fibrillation, transient ischemic attack, hospitalization for congestive heart failure, asthma/chronic obstructive pulmonary disease (COPD), PAD, dyslipidemia, hypertension, and diabetes increased progressively with age. Tobacco and alcohol use decreased relative to age.
Age-related differences in the presentation and clinical management of outpatients with CAD
There were significant age-related differences among both men and women ( Men of all ages were significantly more likely to have undergone CABG than women (Table 1) . In patients <65 years of age percutaneous coronary interventions were more common in men than women, but in older patients the proportion of men and women having these interventions was similar. 
Discussion
Our analysis reveals a number of gender-and age-related differences among stable outpatients with CAD. These findings have important clinical implications. The positive impact of improvements in the prevention and treatment of CAD has resulted in an increased number of elderly patients of both genders living as outpatients and needing targeted care. In terms of risk factors, older patients have lower heart rates compared with those aged <65 years, but higher systolic blood pressure, a higher prevalence of diabetes, and are less likely to be current smokers. There were also significant differences in current medications used by different age groups. Increasing age was associated with a reduced likelihood of receiving effective cardiac therapies such as ACE inhibitors, lipid-lowering agents and beta-blockers, but more symptomatic therapy.
This paradox of less intensive use of evidence based preventive therapies in patients recognized to be at higher risk may reflect attempts by physicians to limit the number of cardiovascular medications in elderly patients who often need other drugs for comorbid conditions, or to the questionable belief that in elderly patients symptom relief is more important than prognosis.
A number of gender-related differences were also relevant. When compared with their age-matched male counterparts, women with CAD were older, less likely to be current smokers, but performed less or no physical activity. Women had more history of diabetes, high blood pressure and angina, yet were less likely than men to undergo coronary artery angiography as well as non-invasive tests for myocardial ischemia. This latter discrepancy is probably related to the rather low specificity of exercise testing in women. As a consequence, women are less likely than men to undergo PCI or CABG.
Pharmacological therapy for CAD also differed between the sexes. Women were more likely to receive calcium channel blockers, but less ACE inhibitors, more anti-diabetic drugs, but less statins than men. There were no differences in the use of beta-blockers between men and women.
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Other studies have also shown that men are significantly more likely than women to undergo revascularisation with both CABG and PCI [14, 17, 28] . The reason for this discrepancy is unclear. Physicians appear to be less concerned about CAD in women as, despite the higher degree of angina, women received fewer referrals for coronary angiography. It is also possible that the perception of CAD is less in women than in men so that they consult their physicians less frequently. In the past, revascularisation procedures were associated with more complications in women than men, but technical advances in the last decade have greatly improved outcomes in women [29] . Other reasons for the discrepancy could be linked to differences in clinical judgment or to gender differences in the severity and extent of diseased coronary arteries. In the current study, men had more severe coronary stenoses than women, which may in part explain the lower rate of procedures in women. However, women were also less likely to be receiving recommended treatment with ACE inhibitors and lipid-lowering drugs than their male counterparts. The physician's perception of either anticipated adverse drug reactions or less severe disease may influence their decision to prescribe these medications for women [30] . When taken together, these data suggest the need to increase awareness of CAD in women both among physicians and the female population.
Other studies have reported similar findings [7, 9, 11-12, 14, 17, 25] . However, many of these were completed over a decade ago and may not reflect current clinical practice.
Furthermore, many have focused on specific subgroups of patients with a particular manifestation of disease such as stable angina or acute coronary syndromes. Others focused on populations from randomized clinical trials with their more narrowly defined inclusion/exclusion criteria. The CLARIFY data are an important addition to the literature as they provide robust contemporary information about the characteristics, management, and outcomes of a large population of stable CAD outpatients across a variety of geographic and practice settings. Furthermore, the entire clinical management pathway of patients with stable CAD was examined, rather than restricting the study to a limited number of healthcare interventions.
'Real-life' studies such as CLARIFY offer the advantage that they provide data on a heterogeneous patient population that includes groups who are often under-represented in randomized clinical trials. However, as a non-randomized, observational study, CLARIFY is subject to certain limitations and potential biases. We did not collect information about the adverse effects related to the use of medications, or reasons by patients as well as physicians for not using the medications or undergoing cardiac interventions. Finally, we did not examine the effect of potential confounders when evaluating gender-and age-differences in patients' characteristics and CAD management. However, despite these limitations, the study provides a useful insight into current practice with regard to the characteristics and management of outpatients with stable CAD.
The CLARIFY data reveal that despite the attention that has been focused on gender and age-related differences over the past 20 years, the disparities have remained largely unchanged over time. Women and the elderly form a major part of the population that characterizes contemporary outpatients with stable CAD , yet, despite appearing at higher risk of subsequent events, based on increased prevalence of risk factors and more frequent history of CV events, they receive less intensive preventive evidence based therapies. In high risk patients, particularly those with established CAD, vigorous preventive measures are warranted at all ages and in both sexes. Further work is required to improve our understanding of the age and gender differences in patient characteristics and CAD management identified in the CLARIFY registry. 
